What changed in GLAUKOS Corp's latest annual report
In the year ended 31 Dec 2025, GLAUKOS Corp's revenue rose 32.3% to USD 507.44m, from USD 383.48m; cash and cash equivalents fell 46.5% to USD 90.81m, from USD 169.63m; shareholders' equity fell 14.4% to USD 656.15m, from USD 766.93m.
Year ended 31 Dec 2025. Source: 10-K filed 23 Feb 2026, read it on SEC EDGAR.
USD 383.48m to USD 507.44m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 383.48m | 507.44m | Up 32.3% |
| Net income | -146.37m | -187.69m | Not comparable |
| Total assets | 974.76m | 893.49m | Down 8.3% |
| Total liabilities | 207.82m | 237.33m | Up 14.2% |
| Cash and cash equivalents | 169.63m | 90.81m | Down 46.5% |
| Shareholders' equity | 766.93m | 656.15m | Down 14.4% |
Questions people ask
Did GLAUKOS Corp's revenue grow last year?
Revenue grew 32.3%, from USD 383.48m to USD 507.44m in the year ended 31 Dec 2025.
Is GLAUKOS Corp profitable?
Not in its latest year: it reported a net loss of USD 187.69m in the year ended 31 Dec 2025. The year before: a net loss of USD 146.37m.
How much cash and debt does GLAUKOS Corp have?
At its latest year end (31 Dec 2025), GLAUKOS Corp reported cash and cash equivalents of USD 90.81m.
Where do these numbers come from?
From GLAUKOS Corp's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with GLAUKOS Corp?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Surgical & Medical Instruments & Apparatus companies
- Stryker CorpLong-term debt up 21.9%
- 3M CompanyShareholders' equity up 22.4%
- Boston Scientific CorporationCash and cash equivalents up 374.6%
- Becton, Dickinson And CompanyCash and cash equivalents down 62.7%
- Medline Inc.Cash and cash equivalents up 874.4%
- ResMed Inc.Long-term debt down 39.3%
- Dexcom, Inc.Cash and cash equivalents up 51.4%
- West Pharmaceutical Services, Inc.Cash and cash equivalents up 63.3%